Mohammed Azam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammed Azam has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Michel Chalhoub
Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, USA
3 shared publications - Saad Habib
Internal Medicine, Staten Island University Hospital/Northwell Health, Staten Island, USA
3 shared publications - Abdul Hasan Siddiqui
Pulmonary and Critical Care Medicine, University of Illinois at Urbana-Champaign, Champaign, USA
2 shared publications - Kartikeya Rajdev
Pulmonary, Critical Care & Sleep Medicine, University of Nebraska Medical Center, Omaha, NE, USA
2 shared publications - Abdul Hasan Siddiqui
Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, USA
1 shared publication - Asma Memon
Department of Internal Medicine, Staten Island University Hospital, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 28, 100867
Septic emboli of the lung due to Fusobacterium necrophorum, a case of Lemierre's syndrome
- 1 January 2019
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 28, 100867
Open AccessSeptic emboli of the lung due to Fusobacterium necrophorum, a case of Lemierre's syndrome
- Open Access
- 29 October 2018
- Published by Springer Nature in Cureus
- Vol. 10 (10) , e3512
Pulmonary Cavitary Disease Secondary to Mycobacterium xenopi Complicated by Respiratory Failure
Non-tuberculous mycobacteria (NTM) are a significant cause of pulmonary infection worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment, as in the case of a human immunodeficiency virus infection, or a structural lung disease to cause a clinical disease. Comorbidities have an essential role in M. xenopi occurrence. Herein, we present a rare case of pulmonary cavitary disease caused by M. xenopi complicated by respiratory failure and superinfection in a patient with a chronic obstructive pulmonary disease. An 81-year-old woman presented to the hospital with the chief concerns of shortness of breath and productive cough lasting a few weeks before presentation. A computed tomography scan of the chest showed a right upper lobe, thick-walled, cavitary lesion measuring 2.1 cm x 4.3 cm x 3.1 cm with associated bronchiectasis and pleural parenchymal scarring. One year ago, the patient underwent bronchoscopy for a right upper lobe cavitary lesion, which revealed M. xenopi on bronchoalveolar lavage culture. During the current admission, she was started on rifampin, isoniazid, ethambutol, and clarithromycin because the M. xenopi was clinically significant and fulfilled the American Thoracic Society diagnostic criteria for NTM lung disease. A diagnosis of NTM pulmonary disease does not necessarily suggest that treatment is required. The distinction between colonization and illness may be difficult upon the isolation of M. xenopi. A patient-centered approach is essential given that M. xenopi is often considered a commensal pathogen. When treatment is required, a multidrug approach with an individualized, optimal duration of therapy should be considered.
- 29 October 2018
- Published by Springer Nature in Cureus
- Vol. 10 (10) , e3512
Open AccessPulmonary Cavitary Disease Secondary to Mycobacterium xenopi Complicated by Respiratory Failure
Non-tuberculous mycobacteria (NTM) are a significant cause of pulmonary infection worldwide and can be clinically challenging. Mycobacterium xenopi (M. xenopi) has low pathogenicity and usually requires either host immune impairment, as in the case of a human immunodeficiency virus infection, or a structural lung disease to cause a clinical disease. Comorbidities have an essential role in M. xenopi occurrence. Herein, we present a rare case of pulmonary cavitary disease caused by M. xenopi complicated by respiratory failure and superinfection in a patient with a chronic obstructive pulmonary disease. An 81-year-old woman presented to the hospital with the chief concerns of shortness of breath and productive cough lasting a few weeks before presentation. A computed tomography scan of the chest showed a right upper lobe, thick-walled, cavitary lesion measuring 2.1 cm x 4.3 cm x 3.1 cm with associated bronchiectasis and pleural parenchymal scarring. One year ago, the patient underwent bronchoscopy for a right upper lobe cavitary lesion, which revealed M. xenopi on bronchoalveolar lavage culture. During the current admission, she was started on rifampin, isoniazid, ethambutol, and clarithromycin because the M. xenopi was clinically significant and fulfilled the American Thoracic Society diagnostic criteria for NTM lung disease. A diagnosis of NTM pulmonary disease does not necessarily suggest that treatment is required. The distinction between colonization and illness may be difficult upon the isolation of M. xenopi. A patient-centered approach is essential given that M. xenopi is often considered a commensal pathogen. When treatment is required, a multidrug approach with an individualized, optimal duration of therapy should be considered.
- Open Access
- 25 August 2018
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 25, 158-160
Actinomyces viscosus causing disseminated disease in a patient on methotrexate
- 25 August 2018
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 25, 158-160
Open AccessActinomyces viscosus causing disseminated disease in a patient on methotrexate